Koken Company, Limited

Opticol Corporation

Cornell Research Foundation Inc.

Other

Shiseido Company, Limited

Sumitomo Pharmaceuticals Company Limited

Collagen Development Corp.

Dainippon Sumitomo Pharma Co., Ltd.

Katakura Chikkarin Co., Ltd.

Optical Corp.

Teruo Miyata

Masayasu Furuse

Yasuharu Noishiki

Albert L Rubin

Kurt H Stenzel

Michael W Dunn

Kazuhiko Kodaira

Yoshimitsu Kuroyanagi

Hiroshi Itoh

Keiji Fujioka

Shigeji Sato

Yoshio Sasaki

Yasuhara Noishiki

Toshio Taira

Tetsuro Namiki

Hiromi Naito

Takashi Suzuki

Takahiro Ochiya

Akiko Tanaka

Katsutoshi Yoshizato

Taichiro Akiyama

Masaaki Terada

Naoki Tominaga

Makoto Tsunenaga

Toshio Nishiyama

Takeshi Ogawara

Hitoshi Koyanagi

Manabu Seno

Hiraku Ito

Takeaki Miyamoto

Shunji Kasai

Toshihiro Akaike

Shinichi Namiki

Toru Yamashita

Mutsumi Fukuyama

Atsushi Kanai

Hitoshi Higashijima

Takashi Kimura

Eisaburo Imamura

Tadatomo Kawai

Takashi Hamano

The present invention relates to gene preparations comprising desired genes or vectors containing desired genes integrated there into and carriers for supporting the same. The carrier is preferably a soluble collagen such as atelocollagen and may further include an additive. The invention also encompasses methods for delivering genes to cells employing the gene preparation.

Gene preparations

An auxiliary agent for ophthalmic surgery is based on collagen and, after the completion of surgery, undergoes a lowering in viscosity, and thus can be easily removed. This agent is a neutral solution of collagen which is transparent at a neutral pH and has a denaturation temperature below the intraocular temperature, or a derivative thereof. The agent has a visual light transmission at 400 nm of at least 90% of that before the denaturation, when solution is heated to cause denaturation.

Collagen-based auxiliary agent for ophthalmic surgery

A method of obstructing the lacrimal canaliculi by infusing therein a solution or liquid dispersion containing a gel forming material, such having collagen as the main ingredient in the range of 1 mg/ml to 70 mg/ml for improving the symptoms of dry eye.

Method for obstructing lacrimal canaliculi with infusable solution or

The invention relates to a vascular prosthesis wherein, fragments of biological tissues such as vascular tissues, connective tissues, fat tissues and muscular tissues and/or cells composing vascular walls such as vascular endothelial cells, smooth muscle cells and fibroblast cells are deposited and captured within the wall of a vascular prosthesis substrate; a manufacturing method comprising the steps of immersing a vascular prosthesis substrate into a dispersed solution of fragments of biological tissues such as vascular tissues, connective tissues, fat tissues and muscular tissues and/or cells composing vascular walls such as vascular endothelial cells, smooth muscle cells and fibroblast cells, and depositing and capturing the cells and/or tissue fragments on the inner wall and within the wall of the vascular prosthesis from one side to the other side of the vascular prosthesis substrate wall by providing a pressure differential between the outside and the inside of the vascular prosthesis substrate; and a substrate suitable for manufacturing a vascular prosthesis having a porous membrane having pores capable of trapping tissue fragments, or a laminate structure with such a membrane and another porous membrane having pores not large enough to pass the cells or tissue fragments.

Vascular prosthesis, manufacturing method of the same, and substrate for

The present invention provides an intracorporeally injectable non-toxic composition of atelocollagen having an excellent, long-lasting skin swelling effect due to its low viscosity, good fluidity, easy injectability and low antigenicity (without calcification) properties. The composition is prepared by treating an aqueous suspension of atelocollagen with a buffer for physiological conditions. The suspension can have atelocollagen content of 55 to 75 mg/ml, where approximately 20 to 100% by weight of atelocollagen is cross-linked with a polyepoxy compound.

Intracorporeally injectable composition for implanting highly

A method for drying a wetted molded product of pasty high viscous composition which comprises subjecting the molded product to a dehydration process while wholly or partially contacting the product with an open-cell foamed hydrophobic porous membrane.

Method for drying wetted molded product

A hyaluronic acid-containing aqueous solution or aqueous dispersion of collagen having a pH of from about 6.5 to about 8.0 and an osmolality of from about 230 to about 320 mOsm/kgH.sub.2 O. The aqueous solution or the aqueous dispersion of collagen is useful as an agent for correction and reparation of a depressed part of or a void in soft tissue of mammals.

Hyaluronic acid-containing aqueous solution or aqueous dispersion of

A biomaterial excellent in biocompatibility comprising a composite material of an N-acylchitosan and collagen is described. This biomaterial is suitable for used as a wound dressing material, vascular prosthesis, artificial skin or hemostatic agent.

Biomaterial comprising a composite material of a chitosan derivative and

A bioprosthetic valve made from a biological tissue containing collagen which has been cross-linked with a polyepoxy compound is disclosed. The valve has excellent biocompatibility and is durable and is free from calcification.

Bioprosthetic valve

An artifical skin comprising an insoluble atelocollagen sheet and an epidermal cell layer cultured only on one surface of the sheet, and a method of producing the same are disclosed, which method includes the steps of: forming an insoluble atelocollagen sheet; inoculating epidermal cells only on one surface of the atelocollagen sheet; and suspending the atelocollagen sheet in a liquid culture medium to culture the epidermal cells, thereby forming an epidermal cell layer.

Method of producing an artifical skin

A method for preparing a sustained release formulation utilizing collagen and/or gelatin as a carrier, which comprises the steps:

Method for producing sustained release formulation

This invention relates to a surfactant with less toxicity and irritation against the human body and a production process thereof. The surfactant is produced by the acylation of the side chain amino radicals of collagen or gelatine with an aliphatic acid having 2 to 26 carbon atoms; it is used as an emulsifier and an antiseptic for cosmetics.

Surfactant composed of acylated collagen or acylated gelatine and a

An antithrombogenic medical material with a remarkable antithrombogenic property and histocompatibility as well as sufficient physical strength, formed by fixing a heparinized collagen to a synthetic polymer material is provided. And a method of preparing an antithrombogenic medical material is provided, wherein a synthetic polymer material is subjected to a coating or impregnating treatment with a collagen-containing solution, followed by heparinization of the collagen, and the heparinized collagen is fixed to the synthetic polymer material. This method allows manufacturing of antithrombogenic medical material with ease.

Antithrombogenic medical material and method of preparing same

In a method of preparing an antithrombogenic medical material having a heparinized collagen as an antithrombogenic component, there is provided a method comprising the steps of fixing a protamine to a collagen through a polyepoxy compound, and heparinizing the collagen by fixing heparin to the protamine.

Method of preparing antithrombogenic medical materials

Growing community of inventors

Tokyo, Japan

Teruo Miyata